Characterization of a monoclonal antibody LpMab-7 recognizing non-PLAG domain of podoplanin

Hiroharu Oki[1,2,3], Mika K. Kaneko[1,3], Satoshi Ogasawara[1,3], Yuta Tsujimoto[1], Xing Liu[1,2], Masato Sugawara[2], Yuya Takakubo[2], Michiaki Takagi[2], Yukinari Kato[1]

[1]Department of Regional Innovation, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi 980-8575, Japan; [2]Department of Orthopaedic Surgery, Yamagata University Faculty of Medicine, 2-2-2 Iida-nishi, Yamagata 990-9585, Japan

Corresponding author: Yukinari Kato
Department of Regional Innovation, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi 980-8575, Japan
E-mail: yukinari-k@bea.hi-ho.ne.jp; or, yukinarikato@med.tohoku.ac.jp
TEL/FAX: +81-22-717-8207
[3]Theses authors contributed equally to this work.

Key words: monoclonal antibody, podoplanin, CasMab, epitope, PLAG domain

Podoplanin (PDPN/Aggrus/T1α), a platelet aggregation-inducing type I transmembrane sialoglycoprotein, is involved in tumor invasion and metastasis. Furthermore, podoplanin expression was reported to be involved in poor prognosis of several cancers. Although many anti-podoplanin mAbs such as NZ-1 and D2-40 have been established, those epitopes are limited to platelet aggregation-stimulating (PLAG) domain of podoplanin. In this study, we developed and characterized a novel anti-podoplanin mAb, LpMab-7, which is more sensitive than NZ-1 in immunohistochemistry. We identified the minimum epitope of LpMab-7 as Arg79–Leu83 of human podoplanin, which is different from PLAG domain, using ELISA, Western-blot, and flow cytometry. Because LpMab-7 has high sensitivity against podoplanin, LpMab-7 is expected to be useful for molecular targeting therapy for podoplanin-expressing cancers.

Introduction

Podoplanin is a platelet aggregation-inducing type I transmembrane sialoglycoprotein, which is involved in tumor invasion and metastasis.[1, 2] Expression of podoplanin has been reported in many tumors including malignant brain tumors, mesotheliomas, lung cancer, esophageal cancer, testicular tumors, bladder cancer, and osteosarcoma.[1, 3-14] Until now, several physiological functions of podoplanin have been reported. The podoplanin-CLEC-2 interaction is important for platelet aggregation and embryonic blood-lymphatic vascular separation.[1, 2, 15-19] Podoplanin is also very useful for detecting lymphatic endothelial cells.[20-22] The development of ectopic lymphoid follicles is dependent on Th17-expressing podoplanin.[23] Local sphingosine-1-phosphate release after podoplanin-CLEC-2-mediated platelet activation is critical for high endothelial venule integrity during immune responses.[24] Furthermore, the activation of CLEC-2 by podoplanin rearranges the actin cytoskeleton in dendritic cells to promote efficient motility along stromal surfaces.[25]

Many anti-podoplanin mAbs have been produced, and those mAbs are useful for detecting podoplanin, which functions physiologically in normal tissues. Almost all anti-podoplanin mAbs react with platelet aggregation-inducing (PLAG) domain of human podoplanin.[7, 26-30] Matsui *et al*. previously reported that rabbit polyclonal antibodies produced by immunizing recombinant rat podoplanin also recognize PLAG domains, which were shown to be immunodominant antigenic sites.[31] Recently, we established the platform to produce cancer-specific mAbs (CasMabs).[32] Using CasMab methods, we could produce several anti-podoplanin mAbs against a non-PLAG domain. In this study, we characterized a novel anti-podoplanin mAb, LpMab-7, which possesses high sensitivity against podoplanin.

Materials and Methods

Cell lines and tissues

Chinese hamster ovary (CHO)-K1, SaOS2, and U-2 OS cell lines were obtained from the American Type Culture Collection (ATCC, Manassas, VA). OST cell

line was obtained from the RIKEN BioResource Center (Ibaraki, Japan).[33] HuO9 cell line was obtained from the Japanese Cancer Research Resources Bank (Tokyo, Japan).[33] NOS-1 cell line was donated by Dr. Teiichi Motoyama.[34] CHO-K1 cells were cultured in RPMI 1640 medium (Wako Pure Chemical Industries, Ltd., Osaka, Japan) supplemented with 10% heat-inactivated fetal bovine serum (FBS; Life Technologies Corp., Carlsbad, CA), 2 mM L-glutamine (Life Technologies Corp.), 100 units/ml of penicillin, and 100 μg/ml of streptomycin (Life Technologies Corp.) at 37°C in a humidified atmosphere of 5% CO_2 and 95% air. SaOS2, HuO9, U-2 OS, OST, and NOS-1 cells were cultured in Dulbecco's Modified Eagle's Medium (DMEM; Wako Pure Chemical Industries Ltd.) supplemented with 10% heat-inactivated FBS, 2 mM L-glutamine, 100 units/ml of penicillin, and 100 μg/ml of streptomycin. This study examined osteosarcoma patients who underwent surgery at Yamagata University Hospital.[35] The ethical committee of the Yamagata University Faculty of Medicine approved our study. Informed consent for obtaining samples and for subsequent data analyses was obtained from each patient or the patient's guardian.

Flow cytometry

Cell lines were harvested by brief exposure to 0.25% Trypsin/1 mM EDTA (Wako Pure Chemical Industries Ltd.).[16] After washing with phosphate buffered saline (PBS), the cells were treated with primary antibodies (1 μg/ml) for 30 min at 4°C, followed by treatment with Alexa Fluor 488 conjugated anti-mouse IgG or anti-rat IgG (Cell Signaling Technology, Inc., Danvers, MA). Fluorescence data were collected using a Cell Analyzer EC800 (Sony Corp., Tokyo, Japan).

Western-blot analyses

Cell lysates (10 μg) were boiled in SDS sample buffer (Nacalai Tesque, Inc., Kyoto, Japan).[36] The proteins were electrophoresed on 5–20% polyacrylamide gels (Wako Pure Chemical Industries Ltd.) and were transferred onto a PVDF membrane (EMD Millipore Corp., Billerica, MA). After blocking with SuperBlock T20 (PBS) Blocking Buffer (Thermo Fisher Scientific Inc., Waltham, MA), the membrane was incubated with primary antibodies (1 μg/ml), then with peroxidase-conjugated secondary antibodies (Dako, Glostrup, Denmark; 1/1,000 diluted), and developed with the ECL-plus reagent (Thermo Fisher Scientific Inc.) using a Sayaca-Imager (DRC Co. Ltd., Tokyo, Japan).

Immunohistochemical analyses

Podoplanin protein expression was detected immunohistochemically in paraffin-embedded tumor specimens. Briefly, 4-μm-thick histologic sections were deparaffinized in xylene and rehydrated. Then, they were autoclaved in citrate buffer (pH 6.0; Dako) for 20 min. Sections were incubated with 5 μg/ml of primary antibodies overnight at 4 °C followed by treatment with an LSAB+ kit or Envision+ kit (Dako). Color was developed using 3, 3-diaminobenzidine tetrahydrochloride (DAB; Dako) for 10 min, and then the sections were counterstained with hematoxylin (Wako Pure Chemical Industries Ltd.).

Production of podoplanin mutants

The amplified human podoplanin cDNA was subcloned into a pcDNA3 vector (Life Technologies Corp.) and a FLAG epitope tag was added at the C-terminus. Substitution of amino acids to alanine in podoplanin was performed using a QuikChange Lightning site-directed mutagenesis kit (Agilent Technologies Inc., Santa Clara, CA).[32, 37] CHO-K1 cells were transfected with the plasmids using a Gene Pulser Xcell electroporation system (Bio-Rad Laboratories Inc., Philadelphia, PA).

Enzyme-linked immunosorbent assay (ELISA)

Podoplanin peptides were immobilized on Nunc Maxisorp 96-well immunoplates (Thermo Fisher Scientific Inc.) at 1 μg/ml for 30 min.[16] After blocking with SuperBlock T20 (PBS) Blocking Buffer, the plates were incubated with culture supernatant or purified mAbs (1 μg/ml) followed by 1:1,000 diluted peroxidase-conjugated anti-mouse IgG (Dako). The enzymatic reaction was conducted with a 1-Step Ultra TMB-ELISA (Thermo Fisher Scientific Inc.), and was stopped using 1M H_2SO_4. The optical density was measured at 450 nm using an iMark microplate reader (Bio-Rad Laboratories Inc.). These reactions were performed with a volume of 50 μl at 37°C.

Results

Characterization of a novel anti-podoplanin monoclonal antibody (mAb), LpMab-7

We recently immunized mice with human podoplanin (PDPN)-expressing LN229 glioma cells (LN229/PDPN), which possess cancer-type glycan patterns including highly sulfated polylactosamine and aberrant sialylation, and developed a novel anti-podoplanin mAb, LpMab-7 (IgG_1, kappa).[32] First, podoplanin expression of 5 osteosarcoma cell lines (SaOS2, HuO9, U-2 OS, OST, and NOS-1) was investigated by flow cytometry and Western-blot analysis. An anti-podoplanin mAb NZ-1 (rat IgG_{2a}, lambda) was used for positive control of detecting human podoplanin.[7] As shown in Fig. 1a and 2b, both

NZ-1 and LpMab-7 recognized podoplanin of U-2 OS. LpMab-7 detected 35-kDa band, which was not detected by NZ-1 (Fig. 1b). This 35-kDa band was also detected in CHO/PDPN or LN229/PDPN in our previous reports.[32] Immunohistochemical analysis showed that LpMab-7 detected podoplanin more sensitively than NZ-1 (Fig. 1c). The membranous/cytosolic staining pattern was observed. These results indicated that a novel anti-podoplanin mAb, LpMab-7 is much more useful in immunohistochemistry than previously established anti-podoplanin mAbs.

Epitope mapping by ELISA, flow cytometry, and Western-blot analysis

To determine the LpMab-7 epitope, we first performed ELISA using several deletion mutants of human podoplanin (Table 1). NZ-1 reacted with 38-51 amino acids of human podoplanin (hpp38-51) that is platelet aggregation-inducing (PLAG) domain. In contrast, LpMab-7 strongly recognized 69-88 amino acids of human podoplanin (hpp69-88), indicating that LpMab-7 epitope does not include *O*-glycan and is not different from PLAG domain. We next performed an additional ELISA assay using 20 synthetic peptides, which include a point mutation among 75-94 amino acids of human podoplanin (Table 2). LpMab-7 did not react with R79A, I80A, E81A, D82A, and L83A, indicating that the critical amino acid sequence for LpMab-7 is RIEDL. To confirm this result, we performed flow cytometry and Western-blot analysis. Flow cytometric analysis revealed that LpMab-7 did not react with I80A, E81A, and L83A, and very weakly recognized R79A and D82A, indicating that Ilu80, Glu81, and Leu83 are much more important for LpMab-7 (Fig. 2a). Western-blot analysis also showed that LpMab-7 reaction was lost in point mutations of 79-83 amino acids (Fig. 2b). Taken together, the podoplanin epitope of LpMab-7 is Arg79-Leu83, and Ilu80, Glu81, and Leu83 are the most important amino acids.

Discussion

Until now, other groups and we have developed many anti-podoplanin mAbs. To neutralize platelet aggregation activity by blocking the association between podoplanin and CLEC-2, we produced NZ-1 mAb by immunizing rats with synthetic peptides of podoplanin PLAG domain.[7] NZ-1 possesses very high binding-affinity, which was clarified by several methods including BIAcore, ELISA, flow cytometry, and Scatchard analysis.[14, 38] NZ-1 inhibited tumor cell-induced platelet aggregation and tumor metastasis by its neutralizing activity, indicating that NZ-1 is a candidate of anti-metastatic neutralizing mAb.[7, 16, 36] Furthermore, NZ-1 was highly internalized into glioma cell lines and also accumulated efficiently into tumors *in vivo*.[14] NZ-1 and its rat-human chimeric anti-podoplanin antibody (NZ-8) possess antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) against podoplanin-expressing glioblastoma or malignant mesothelioma cell lines.[10, 36] Recently, we have developed the novel platform, the CasMab method, to produce mAbs against membranous glycoproteins.[32] Using the CasMab method, we can obtain not only cancer-specific mAbs (CasMabs) but also non-CasMabs. Intriguingly, non-CasMabs also include the glycan within those epitopes or detects specific conformation of membranous glycoproteins expressed in cancers.[32] LpMab-7 recognized the usual 40-kDa band and the additional 35-kDa band, which has not been detected by previously reported anti-podoplanin mAbs. This 35-kDa band might be a low glycosylated form. Taken together, the ability to detect 35-kDa band might lead to the high sensitivity of LpMab-7 in immunohistochemistry against podoplanin-expressing tumors. In this report, we compared the reactivity of NZ-1 (rat IgG_{2a}, lambda) and LpMab-7 (mouse IgG_1, kappa). To remove the possibility that the difference of sensitivity in immunohistochemistry occurred by secondary antibodies, we also examined the difference of sensitivity between D2-40 (mouse IgG_1, kappa) and LpMab-7. D2-40 is commercially available and the most used mAb against human podoplanin in pathology or histology because D2-40 is also known as a lymphatic endothelial marker.[26] However, the intensity of LpMab-7 is much higher than that of D2-40 in immunohistochemistry of osteosarcomas (data not shown), demonstrating that LpMab-7 sensitivity is not dependent on the species and the subclass. Indeed, there are many immunohistochemical methods suitable for each mAb; therefore, we should further consider the other methods for comparing those anti-podoplanin mAbs. Although ADCC and CDC activities are very important for an antibody-based molecular targeting therapy, we could not investigate those activities because the subclass of LpMab-7 is IgG_1. The conversion of subclass into human IgG_1 or mouse IgG_{2a} is necessary to demonstrate ADCC/CDC activities. In conclusion, LpMab-7 is expected to be useful for molecular targeting therapy for podoplanin-expressing cancers.

Acknowledgements

We thank Takuro Nakamura, Noriko Saidoh, and Kanae Yoshida for their excellent technical assistance.

This work was supported in part by the Platform for Drug Discovery, Informatics, and Structural Life Science (PDIS) from the Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan (Y.K.); by the Basic Science and Platform Technology Program for Innovative Biological Medicine from MEXT of Japan (Y.K.); by the Regional Innovation Strategy Support Program from MEXT of Japan (Y.K.); and by a Grant-in-Aid for Scientific Research (C) (M.K.K., Y.K.) and a Grant-in-Aid for Young Scientists (B) (S.O.) from MEXT of Japan.

Author Disclosure Statement

The authors have no financial interests to disclose.

Reference

1. Kato Y, Fujita N, Kunita A, Sato S, Kaneko M, Osawa M, Tsuruo T: Molecular identification of Aggrus/T1alpha as a platelet aggregation-inducing factor expressed in colorectal tumors. J. Biol. Chem. 2003;278:51599-51605.

2. Kaneko MK, Kato Y, Kitano T, Osawa M: Conservation of a platelet activating domain of Aggrus/podoplanin as a platelet aggregation-inducing factor. Gene. 2006;378:52-57.

3. Kato Y, Sasagawa I, Kaneko M, Osawa M, Fujita N, Tsuruo T: Aggrus: A diagnostic marker that distinguishes seminoma from embryonal carcinoma in testicular germ cell tumors. Oncogene. 2004;23:8552-8556.

4. Martin-Villar E, Scholl FG, Gamallo C, Yurrita MM, Munoz-Guerra M, Cruces J, Quintanilla M: Characterization of human PA2.26 antigen (T1alpha-2, podoplanin), a small membrane mucin induced in oral squamous cell carcinomas. Int. J. Cancer. 2005;113:899-910.

5. Kato Y, Kaneko M, Sata M, Fujita N, Tsuruo T, Osawa M: Enhanced expression of Aggrus (T1alpha/podoplanin), a platelet-aggregation-inducing factor in lung squamous cell carcinoma. Tumor Biol. 2005;26:195-200.

6. Yuan P, Temam S, El-Naggar A, Zhou X, Liu D, Lee J, Mao L: Overexpression of podoplanin in oral cancer and its association with poor clinical outcome. Cancer. 2006;107:563-569.

7. Kato Y, Kaneko MK, Kuno A, Uchiyama N, Amano K, Chiba Y, Hasegawa Y, Hirabayashi J, Narimatsu H, Mishima K, Osawa M: Inhibition of tumor cell-induced platelet aggregation using a novel anti-podoplanin antibody reacting with its platelet-aggregation-stimulating domain. Biochem. Biophys. Res. Commun. 2006;349:1301-1307.

8. Mishima K, Kato Y, Kaneko MK, Nakazawa Y, Kunita A, Fujita N, Tsuruo T, Nishikawa R, Hirose T, Matsutani M: Podoplanin expression in primary central nervous system germ cell tumors: a useful histological marker for the diagnosis of germinoma. Acta Neuropathol. (Berl). 2006;111:563-568.

9. Mishima K, Kato Y, Kaneko MK, Nishikawa R, Hirose T, Matsutani M: Increased expression of podoplanin in malignant astrocytic tumors as a novel molecular marker of malignant progression. Acta Neuropathol. (Berl). 2006;111:483-488.

10. Abe S, Morita Y, Kaneko MK, Hanibuchi M, Tsujimoto Y, Goto H, Kakiuchi S, Aono Y, Huang J, Sato S, Kishuku M, Taniguchi Y, Azuma M, Kawazoe K, Sekido Y, Yano S, Akiyama S, Sone S, Minakuchi K, Kato Y, Nishioka Y: A novel targeting therapy of malignant mesothelioma using anti-podoplanin antibody. J. Immunol. 2013;190:6239-6249.

11. Takagi S, Oh-hara T, Sato S, Gong B, Takami M, Fujita N: Expression of Aggrus/podoplanin in bladder cancer and its role in pulmonary metastasis. Int. J. Cancer. 2014;134:2605-2614.

12. Kunita A, Kashima TG, Ohazama A, Grigoriadis AE, Fukayama M: Podoplanin is regulated by AP-1 and promotes platelet aggregation and cell migration in osteosarcoma. Am. J. Pathol. 2011;179:1041-1049.

13. Chandramohan V, Bao X, Kato Kaneko M, Kato Y, Keir ST, Szafranski SE, Kuan CT, Pastan IH, Bigner DD: Recombinant anti-podoplanin (NZ-1) immunotoxin for the treatment of malignant brain tumors. Int. J. Cancer. 2013;132:2339-2348.

14. Kato Y, Vaidyanathan G, Kaneko MK, Mishima K, Srivastava N, Chandramohan V, Pegram C, Keir ST, Kuan CT, Bigner DD, Zalutsky MR: Evaluation of anti-podoplanin rat monoclonal antibody NZ-1 for targeting malignant gliomas. Nucl. Med. Biol. 2010;37:785-794.

15. Kaneko M, Kato Y, Kunita A, Fujita N, Tsuruo T, Osawa M: Functional sialylated

O-glycan to platelet aggregation on Aggrus (T1alpha/podoplanin) molecules expressed in Chinese Hamster Ovary cells. J. Biol. Chem. 2004;279:38838-38843.

16. Kato Y, Kaneko MK, Kunita A, Ito H, Kameyama A, Ogasawara S, Matsuura N, Hasegawa Y, Suzuki-Inoue K, Inoue O, Ozaki Y, Narimatsu H: Molecular analysis of the pathophysiological binding of the platelet aggregation-inducing factor podoplanin to the C-type lectin-like receptor CLEC-2. Cancer Sci. 2008;99:54-61.

17. Kaneko MK, Kato Y, Kameyama A, Ito H, Kuno A, Hirabayashi J, Kubota T, Amano K, Chiba Y, Hasegawa Y, Sasagawa I, Mishima K, Narimatsu H: Functional glycosylation of human podoplanin: glycan structure of platelet aggregation-inducing factor. FEBS Lett. 2007;581:331-336.

18. Suzuki-Inoue K, Kato Y, Inoue O, Kaneko MK, Mishima K, Yatomi Y, Yamazaki Y, Narimatsu H, Ozaki Y: Involvement of the snake toxin receptor CLEC-2, in podoplanin-mediated platelet activation, by cancer cells. J. Biol. Chem. 2007;282:25993-26001.

19. Bertozzi CC, Schmaier AA, Mericko P, Hess PR, Zou Z, Chen M, Chen CY, Xu B, Lu MM, Zhou D, Sebzda E, Santore MT, Merianos DJ, Stadtfeld M, Flake AW, Graf T, Skoda R, Maltzman JS, Koretzky GA, Kahn ML: Platelets regulate lymphatic vascular development through CLEC-2-SLP-76 signaling. Blood. 2010;116:661-670.

20. Breiteneder-Geleff S, Soleiman A, Kowalski H, Horvat R, Amann G, Kriehuber E, Diem K, Weninger W, Tschachler E, Alitalo K, Kerjaschki D: Angiosarcomas express mixed endothelial phenotypes of blood and lymphatic capillaries: podoplanin as a specific marker for lymphatic endothelium. Am. J. Pathol. 1999;154:385-394.

21. Kaji C, Tsujimoto Y, Kato Kaneko M, Kato Y, Sawa Y: Immunohistochemical Examination of Novel Rat Monoclonal Antibodies against Mouse and Human Podoplanin. Acta histochem. cytochem. 2012;45:227-237.

22. Maruyama Y, Maruyama K, Kato Y, Kajiya K, Moritoh S, Yamamoto K, Matsumoto Y, Sawane M, Kerjaschki D, Nakazawa T, Kinoshita S: The effect of podoplanin inhibition on lymphangiogenesis under pathological conditions. Invest Ophthalmol Vis Sci. 2014;55:4813-4822.

23. Peters A, Pitcher LA, Sullivan JM, Mitsdoerffer M, Acton SE, Franz B, Wucherpfennig K, Turley S, Carroll MC, Sobel RA, Bettelli E, Kuchroo VK: Th17 cells induce ectopic lymphoid follicles in central nervous system tissue inflammation. Immunity. 2011;35:986-996.

24. Herzog BH, Fu J, Wilson SJ, Hess PR, Sen A, McDaniel JM, Pan Y, Sheng M, Yago T, Silasi-Mansat R, McGee S, May F, Nieswandt B, Morris AJ, Lupu F, Coughlin SR, McEver RP, Chen H, Kahn ML, Xia L: Podoplanin maintains high endothelial venule integrity by interacting with platelet CLEC-2. Nature. 2013;502:105-109.

25. Acton SE, Astarita JL, Malhotra D, Lukacs-Kornek V, Franz B, Hess PR, Jakus Z, Kuligowski M, Fletcher AL, Elpek KG, Bellemare-Pelletier A, Sceats L, Reynoso ED, Gonzalez SF, Graham DB, Chang J, Peters A, Woodruff M, Kim YA, Swat W, Morita T, Kuchroo V, Carroll MC, Kahn ML, Wucherpfennig KW, Turley SJ: Podoplanin-rich stromal networks induce dendritic cell motility via activation of the C-type lectin receptor CLEC-2. Immunity. 2012;37:276-289.

26. Ogasawara S, Kaneko MK, Price JE, Kato Y: Characterization of anti-podoplanin monoclonal antibodies: critical epitopes for neutralizing the interaction between podoplanin and CLEC-2. Hybridoma. 2008;27:259-267.

27. Takagi S, Sato S, Oh-hara T, Takami M, Koike S, Mishima Y, Hatake K, Fujita N: Platelets promote tumor growth and metastasis via direct interaction between Aggrus/podoplanin and CLEC-2. PLoS One. 2013;8:e73609.

28. Nakazawa Y, Takagi S, Sato S, Oh-hara T, Koike S, Takami M, Arai H, Fujita N: Prevention of hematogenous metastasis by neutralizing mice and its chimeric anti-Aggrus/podoplanin antibodies. Cancer Sci. 2011;102:2051-2057.

29. Marks A, Sutherland DR, Bailey D, Iglesias J, Law J, Lei M, Yeger H, Banerjee D, Baumal R: Characterization and distribution of an oncofetal antigen (M2A antigen) expressed on testicular germ cell tumours. Br. J. Cancer. 1999;80:569-578.

30. Kono T, Shimoda M, Takahashi M, Matsumoto K, Yoshimoto T, Mizutani M,

Tabata C, Okoshi K, Wada H, Kubo H: Immunohistochemical detection of the lymphatic marker podoplanin in diverse types of human cancer cells using a novel antibody. Int. J. Oncol. 2007;31:501-508.

31. Matsui K, Breiteneder-Geleff S, Kerjaschki D: Epitope-specific antibodies to the 43-kD glomerular membrane protein podoplanin cause proteinuria and rapid flattening of podocytes. J Am Soc Nephrol. 1998;9:2013-2026.

32. Kato Y, Kaneko MK: A cancer-specific monoclonal antibody recognizes the aberrantly glycosylated podoplanin. Sci Rep. 2014;4:5924.

33. Ogose A, Motoyama T, Hotta T, Watanabe H, Takahashi HE: Bone formation in vitro and in nude mice by human osteosarcoma cells. Virchows Arch. 1995;426:117-125.

34. Hotta T, Motoyama T, Watanabe H: Three human osteosarcoma cell lines exhibiting different phenotypic expressions. Acta Pathol Jpn. 1992;42:595-603.

35. Liu X, Kato Y, Kaneko MK, Sugawara M, Ogasawara S, Tsujimoto Y, Naganuma Y, Yamakawa M, Tsuchiya T, Takagi M: Isocitrate dehydrogenase 2 mutation is a frequent event in osteosarcoma detected by a multi-specific monoclonal antibody MsMab-1. Cancer Med. 2013;2:803-814.

36. Kaneko MK, Kunita A, Abe S, Tsujimoto Y, Fukayama M, Goto K, Sawa Y, Nishioka Y, Kato Y: Chimeric anti-podoplanin antibody suppresses tumor metastasis through neutralization and antibody-dependent cellular cytotoxicity. Cancer Sci. 2012;103:1913-1919.

37. Kaneko MK, Tian W, Takano S, Suzuki H, Sawa Y, Hozumi Y, Goto K, Yamazaki K, Kitanaka C, Kato Y: Establishment of a novel monoclonal antibody SMab-1 specific for IDH1-R132S mutation. Biochem. Biophys. Res. Commun. 2011;406:608-613.

38. Fujii Y, Kaneko M, Neyazaki M, Nogi T, Kato Y, Takagi J: PA tag: a versatile protein tagging system using a super high affinity antibody against a dodecapeptide derived from human podoplanin. Protein Expr Purif 2014;95:240-247.



Oki *et al.* Figure 1

Fig. 1. Characterization of a novel anti-podoplanin mAb, LpMab-7. (a) Flow cytometric analysis by NZ-1 and LpMab-7 against osteosarcoma cell lines. Five cell lines were treated with NZ-1 and LpMab-7 (1 μg/ml) for 30 min at 4°C, followed by treatment with Alexa Fluor 488 conjugated anti-rat IgG and anti-mouse IgG, respectively. Fluorescence data were collected using a Cell Analyzer EC800. Red line, NZ-1 or LpMab-7; black line, negative control. (b) Western-blot analysis by NZ-1 and LpMab-7 against osteosarcoma cell lines. AC-15 (α-β-actin), RcMab-1 (α-IDH1), and RMab-3 (α-IDH1) were used as positive control. Total cell lysate of osteosarcoma cell lines (SaOS2, HuO9, U-2 OS, OST, NOS-1) were electrophoresed on 5-20% polyacrylamide gels, and transferred onto a PVDF membrane. After blocking, the membrane was incubated with 1μg/ml of primary antibodies and then with peroxidase-conjugated secondary antibodies; the membrane was detected using a Sayaca-Imager. (c) Immunohistochemical analysis by NZ-1 and LpMab-7 against osteosarcoma tissues. Serial sections were incubated with 5 μg/ml of NZ-1 and LpMab-7, followed by biotin-labeled anti-rat IgG and anti-mouse IgG, respectively. Then, LSAB+ kit was used, and color was developed using DAB and counterstained with hematoxylin. Original magnification: ×200. Scale bar: 100 μm.



Oki *et al.* Figure 2

Fig. 2. Epitope mapping of LpMab-7 by ELISA, flow cytometry, and Western-blot analysis. (a) Point mutants of human podoplanin were treated with NZ-1 and LpMab-7 (1 μg/ml) for 30 min at 4°C, followed by treatment with Alexa Fluor 488 conjugated anti-rat IgG and anti-mouse IgG, respectively. Fluorescence data were collected using a Cell Analyzer EC800. Red line, NZ-1 or LpMab-7; black line, negative control. (b) Total cell lysate of point mutants of human podoplanin were electrophoresed on 5-20% polyacrylamide gels, and transferred onto a PVDF membrane. After blocking, the membrane was incubated with 1μg/ml of primary antibodies and then with peroxidase-conjugated secondary antibodies; the membrane was detected using a Sayaca-Imager.